Search

Your search keyword '"Allergan PLC -- Product development"' showing total 15 results
Start Over Descriptor "Allergan PLC -- Product development" Journal business wire
15 results on '"Allergan PLC -- Product development"'

1. Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation - ResearchAndMarkets.com

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Eisai Company Ltd. -- Product development, Clinical trials, Anti-Alzheimer's disease agents -- Product development, Pharmaceutical industry -- Product development, Alzheimer's disease, Diseases, Business, Business, international
Abstract

DUBLIN -- The 'Alzheimer's Disease Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Summary The clinical trial report, Alzheimer's Disease Global Clinical Trials Review, [...]

Published
2020

2. Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L'Oreal SA & Huons Global Co Ltd - ResearchAndMarkets.com

Subjects
Allergan PLC -- Product development, L'Oreal S.A. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Cosmetics industry -- Product development, Diseases, Business, Business, international
Abstract

DUBLIN -- The 'Wrinkles Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Wrinkles Global Clinical Trials Review, H2, 2019 Summary The clinical trial report, [...]

Published
2020

3. Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS[R] (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Subjects
Allergan PLC -- Product development, Clinical trials, Irritable bowel syndrome -- Complications and side effects, Pharmaceutical industry -- Product development, Linaclotide -- Complications and side effects, Constipation, Business, Business, international, Linzess (Medication)
Abstract

- Phase IIIb study met all primary and secondary endpoints with statistical significance and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with [...]

Published
2019

4. Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D

Subjects
Allergan PLC -- Product development, Clinical trials, Irritable bowel syndrome, Gastrointestinal diseases, Pharmaceutical industry -- Product development, Pain management, Linaclotide, Diarrhea, Business, Business, international
Abstract

- Top-line data from Phase II trial expected in second half 2020 - CAMBRIDGE, Mass. -- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the initiation of patient [...]

Published
2019

5. Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

Subjects
Allergan PLC -- Product development, Clinical trials, Irritable bowel syndrome -- Drug therapy, Constipation -- Drug therapy, Medical research, Pharmaceutical industry -- Product development, Drug approval, Business, Business, international, Linzess (Medication)
Abstract

- Trial designed to more comprehensively evaluate the effect of linaclotide 290 mcg on bothersome abdominal symptoms, including bloating, discomfort and pain, associated with IBS-C - CAMBRIDGE, Mass. -- Ironwood [...]

Published
2018

6. Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C

Subjects
Allergan PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international, Linzess (Medication)
Abstract

Abdominal pain improved 56% with CR1 300 mcg relative to placebo in this trial Companies separately announced Phase IIb data with linaclotide colonic release-2 (CR2) supporting investigation in additional GI [...]

Published
2016

7. Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Clinical trials, Constipation, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

Data also support potential for broad opportunity to treat additional GI indications associated with abdominal pain Companies separately announced Phase IIb data with linaclotide colonic release-1 (CR1) for IBS-C Ironwood [...]

Published
2016

8. Memory Impairment Global Clinical Trials Review, H2, 2015 - Key Vendors are Allergan Plc, Pfizer Inc. & Allied Clinical Management GmbH - Research and Markets

Subjects
Allergan PLC -- Product development, Pfizer Inc. -- Product development, Memory, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/8dl656/memory_impairment) has announced the addition of the 'Memory Impairment Global Clinical Trials Review, H2, 2015' report to their offering. This report provides top line data [...]

Published
2016

9. Essential Tremor Global Clinical Trials Review, H2, 2015 - Key Players are Allergan Plc, Sage Therapeutics & Pfizer Inc. - Research and Markets

Subjects
Allergan PLC -- Product development, Pharmaceutical industry -- Product development, Tremor, Business, Business, international
Abstract

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/6bkpnz/essential_tremor) has announced the addition of the 'Essential Tremor Global Clinical Trials Review, H2, 2015' report to their offering. This report provides top line data [...]

Published
2016

10. Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015 - Key Players are GlaxoSmithKline Plc, Novartis AG & Allergan Plc - Research and Markets

Subjects
Allergan PLC -- Product development, Novartis AG -- Product development, GlaxoSmithKline PLC -- Product development, Irritable bowel syndrome, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/bgw8p8/irritable_bowel) has announced the addition of the 'Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015' report to their offering. The report provides an overview [...]

Published
2016

11. Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015 - Key Vendors: Allergan Plc, ANI Pharmaceuticals, Inc. & Palatin Technologies, Inc. - Research and Markets

Subjects
Allergan PLC -- Product development, ANI Pharmaceuticals Inc. -- Product development, Palatin Technologies Inc. -- Product development, Sexual disorders, Pharmaceutical industry -- Product development, Biological products industry -- Product development, Business, Business, international
Abstract

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/64h2nk/female_sexual) has announced the addition of the 'Female Sexual Dysfunction Global Clinical Trials Review, H2, 2015' report to their offering. Our clinical trial report, Female [...]

Published
2016

12. Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation

Subjects
Allergan PLC -- Product development, Clinical trials, Constipation, Pharmaceutical industry -- Product development, Business, Business, international, Linzess (Medication)
Abstract

CAMBRIDGE, Mass. -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase II clinical trial of linaclotide conducted in adults with opioid-induced constipation (OIC) met its primary endpoint. The [...]

Published
2015

13. Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation

Subjects
Allergan PLC -- Product development, Clinical trials, Irritable bowel syndrome, Constipation, Pharmaceutical industry -- Product development, Business, Business, international, Linzess (Medication)
Abstract

CAMBRIDGE, Mass. & DUBLIN -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today the initiation of a Phase IIb clinical trial evaluating two orally-administered colonic release [...]

Published
2015

14. Ironwood Reports Positive Top-Line Results from Phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation

Subjects
United States. Food and Drug Administration, Allergan PLC -- Product development, Clinical trials, Constipation -- Drug therapy, Pharmaceutical industry -- Product development, Business, Business, international, Linzess (Medication)
Abstract

CAMBRIDGE, Mass. -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase III clinical trial of its 72 mcg dose of linaclotide in adults with chronic idiopathic constipation (CIC) [...]

Published
2015

15. Ironwood Pharmaceuticals Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation

Subjects
Allergan PLC -- Product development, Clinical trials, Irritable bowel syndrome -- Drug therapy, Constipation -- Drug therapy, Pharmaceutical industry -- Product development, Business, Business, international, Linzess (Medication) -- Product development
Abstract

CAMBRIDGE, Mass. -- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation (OIC). [...]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results